Table 4.
Screening for new primary cancers in cancer survivors compared to the NoCancer group
| Reported ever having | NoCancer (n = 519) | Gastric cancer survivor (n = 55) | Colorectal cancer survivor (n = 48) | Lung cancer survivor (n = 16) | Breast cancer survivor (n = 70) | Cervical cancer survivor (n = 29) | Prostate cancer survivor (n = 30) | Liver cancer survivor (n = 7) | Multiple cancer survivor (n = 46) |
|---|---|---|---|---|---|---|---|---|---|
| Gastric cancer screening (men and women, ≥ 50 years) | |||||||||
| Weighted % | 78.6 | – | 93.6 | 74.3 | 84.4 | 86.0 | 88.8 | 100 | 89.6 |
| N (screened/eligible for screening) | 129/166 | – | 41/44 | 12/16 | 53/62 | 16/19 | 26/29 | 6/6 | 38/42 |
| OR (95% CI) for screening | 1 | – |
3.19 (0.90–11.37) |
0.58 (0.17–2.04) |
1.38 (0.60–3.16) |
1.80 (0.52–6.16) |
1.54 (0.41–5.84) |
N/A |
1.67 (0.51–5.47) |
| Colorectal cancer screening (men and women, ≥ 40 years) | |||||||||
| Weighted % | 67.1 | 84.7 | – | 70.7 | 76.9 | 82.6 | 75.0 | 100 | 83.1 |
| N (screened/eligible for screening) | 188/281 | 45/54 | – | 11/16 | 55/68 | 21/26 | 23/30 | 6/6 | 40/46 |
| OR (95% CI) for screening | 1 |
2.02 (0.86–4.73) |
– |
0.85 (0.26–2.80) |
1.44 (0.70–2.95) |
2.19 (0.80–5.96) |
1.10 (0.39–3.06) |
N/A |
1.93 (0.72–5.18) |
| Lung cancer screening (men and women, ≥ 40 years) | |||||||||
| Weighted % | 76.3 | 83.5 | 84.0 | – | 83.8 | 89.0 | 85.0 | 100 | 89.1 |
| N (screened/eligible for screening) | 219/288 | 45/54 | 38/46 | – | 59/70 | 22/25 | 26/30 | 6/6 | 42/46 |
| OR (95% CI) for screening | 1 |
1.24 (0.51–3.03) |
1.30 (0.48–3.55) |
– |
1.39 (0.65–2.96) |
2.37 (0.67–8.31) |
1.42 (0.46–4.45) |
N/A |
2.14 (0.68–6.72) |
| Breast cancer screening (mammography) (women, ≥ 40 years) | |||||||||
| Weighted % | 72.1 | 82.7 | 62.5 | 64.8 | – | 80.5 | – | * | 70.6 |
| N (screened/eligible for screening) | 95/132 | 11/14 | 12/19 | 2/3 | – | 22/26 | – | * | 14/18 |
| OR (95% CI) for screening | 1 |
2.55 (0.52–12.56) |
0.92 (0.35–2.40) |
1.06 (0.08–14.13) |
– |
1.67 (0.48–5.80) |
– | * |
1.27 (0.39–4.11) |
| Cervical cancer screening (pap test) (women, ≥ 20 years) | |||||||||
| Weighted % | 71.4 | 59.6 | 54.3 | 70.4 | 81.8 | * | 54.7 | ||
| N (screened/eligible for screening) | 189/260 | 8/14 | 9/19 | 2/3 | 58/70 | – | – | * | 12/18 |
| OR (95% CI) for screening | 1 |
0.59 (0.14–2.41) |
0.46 (0.15–1.44) |
0.94 (0.07–11.89) |
1.92 (0.88–4.19) |
– | – | * |
0.54 (0.19–1.54) |
| Prostate-specific antigen test (men, ≥ 40 years) | |||||||||
| Weighted % | 17.7 | 31.9 | 42.7 | 42.6 | – | – | – | 76.1 | 65.3 |
| N (screened/eligible for screening) | 28/136 | 12/37 | 12/26 | 6/13 | – | – | – | 3/4 | 17/26 |
| OR (95% CI) for screening | 1 |
0.78 (0.28–2.20) |
1.50 (0.53–4.27) |
1.23 (0.29–5.27) |
– | – | – |
5.45 (0.68–43.39) |
2.26 (0.79–6.46) |
Screening criteria (e.g., age) were based on Ministry of Health, Labor, and Welfare recommendations for the general population for all screening approaches except PSA. For the screening rate, weighted percentages are shown
Values indicate odd ratios and 95% confidence intervals obtained using multiple logistic regression analysis adjusted for age as a continuous variable
Data for the “other cancer” category (n = 88) are not shown
N/A: OR and 95% CI could not be obtained due to the 0 cell
* Five liver cancer survivors were men. One woman did not respond to the question about mammography and Papanicolaou test